[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"rheumatologic-disease\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:rheumatologic-disease":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,45,69,99,122],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":29,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100552184","testimonials-and-navigation-in-rheumatology-100552184",false,"NCT06469788","Testimonials and Navigation in Rheumatology","Improving COVID-19 Vaccine Uptake Among Racial and Ethnic Minority Groups With Rheumatic Diseases","TANGO","Inclusion Criteria:\n\n* Adults (18+ years) with known AIRD\n* Black race and\u002For Latinx ethnicity\n* Individuals who have not obtained the updated COVID-19 vaccine series (self-report)\n\nExclusion Criteria:\n\n-Lack of access to phone","ALL","18 Years",{"count":20,"type":21},1170,"ESTIMATED","INTERVENTIONAL",[24],"NA","The overall goal of this study is to determine whether a novel, multi-modal, patient-directed behavioral intervention initiated in rheumatology clinics is an effective approach to improve uptake of updated COVID-19 vaccine.",[27,28],"Rheumatologic Disease","Autoimmune Diseases",[30,31],"COVID-19 vaccination","Rheumatic Diseases","RECRUITING","2026-05-01",{"date":35,"type":36},"2026-05-06","ACTUAL",{"date":38,"type":36},"2024-12-18",{"date":40,"type":21},"2028-05-31",{"name":42,"class":43},"University of Alabama at Birmingham","OTHER",3,{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":49,"acronym":50,"eligibilityCriteria":51,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":52,"targetDuration":54,"studyType":55,"phases":4,"briefSummary":56,"conditions":57,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":59,"lastUpdatePostDateStruct":60,"startDateStruct":62,"completionDateStruct":64,"leadSponsor":66,"locationsCount":68},"100551508","eular-impact-of-rheumatic-and-musculoskeletal-diseases-survey-100551508","NCT06461000","EULAR Impact of Rheumatic and Musculoskeletal Diseases Survey","ImpactSurvey","Inclusion Criteria:\n\n* 18-year-old at time of baseline survey\n* Living in a EULAR country at time of baseline survey\n* Diagnosed with at least one RMD\n* Valid personal e-mail address\n* Being able to use an internet website\n\nExclusion Criteria:\n\n* none",{"count":53,"type":21},1000,"5 Years","OBSERVATIONAL","The EULAR Impact of RMDs Survey collects first-hand information about the impact of rheumatic and musculoskeletal diseases (RMDs) among patients across and beyond Europe. Through periodic questionnaires, patients will provide information about their healthcare situation, and how the disease affects their social and occupational lives. This data will be an important resource for researchers, healthcare professionals, and patients alike, providing valuable insights into the burden of disease and helping improve the overall care for people living with these conditions.",[27,58],"Musculoskeletal Diseases","2025-11-18",{"date":61,"type":36},"2025-11-21",{"date":63,"type":36},"2025-06-12",{"date":65,"type":21},"2029-06-12",{"name":67,"class":43},"European Alliance of Associations in Rheumatology",1,{"id":70,"slug":71,"hasResults":11,"nctId":72,"briefTitle":73,"officialTitle":74,"acronym":4,"eligibilityCriteria":75,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":76,"enrollmentInfo":77,"targetDuration":4,"studyType":55,"phases":4,"briefSummary":79,"conditions":80,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":90,"lastUpdatePostDateStruct":91,"startDateStruct":93,"completionDateStruct":95,"leadSponsor":97,"locationsCount":68},"100542214","rheumatology-diet-study-100542214","NCT06339957","Rheumatology Diet Study","Title of Study: Eating Habits and Symptom Severity in Autoimmune Diseases: a Patient Survey","Inclusion Criteria:\n\n* Adults (over 18 years old) patients\n* established UCF Health patients\n* diagnosed with rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, dermatomyositis\u002Fpolymyositis, Sjogren's Syndrome, systemic lupus erythematous, scleroderma, osteoarthritis, or fibromyalgia.\n\nExclusion Criteria:\n\n* UCF Students, Faculty or Staff\n* Children or Young Adults Under the age of 18\n* Adults over 65\n* Pregnant Women\n* Prisoners\n* Adults to Unable to Consent","65 Years",{"count":78,"type":21},500,"This study aims to collect information on rheumatology patients' dietary habits, autoimmune disease activity, dietary changes, disease symptom improvements, and perceptions on their dietary habits and how it affects their autoimmune disease. The main objective is to see if rheumatology patients change their dietary habits after their diagnosis of an autoimmune disease and if it subjectively improved their disease symptoms. It will also look at rheumatology patients' expectations for their rheumatologist when it comes to dietary advice and what resources they used to choose their new dietary habits. The study also seeks to measure the interest that rheumatology patients have in pursuing dietary changes as a means of controlling the symptoms of their autoimmune disease. It is expected that patients who changed their eating habits to healthier diets such as a Mediterranean diet would report less severe autoimmune disease symptoms. There are limited dietary recommendations for the management of many rheumatological diseases, so this study seeks to assess rheumatology patients' willingness to try dietary modifications, what improvements they had, and why they decide to make these changes in light of limited information.",[81,27,28,82,83,84,85,86,87,88,89],"Diet Habit","Rheumatoid Arthritis","Psoriatic Arthritis","Ankylosing Spondylitis","Dermatomyositis\u002Fpolymyositis","Sjogren's Syndrome","Systemic Lupus Erythematous","Scleroderma","Fibromyalgia","2024-12-03",{"date":92,"type":36},"2024-12-06",{"date":94,"type":36},"2024-03-01",{"date":96,"type":21},"2025-07-01",{"name":98,"class":43},"University of Central Florida",{"id":100,"slug":101,"hasResults":11,"nctId":102,"briefTitle":103,"officialTitle":103,"acronym":104,"eligibilityCriteria":105,"healthyVolunteers":106,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":107,"targetDuration":109,"studyType":55,"phases":4,"briefSummary":110,"conditions":111,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":113,"lastUpdatePostDateStruct":114,"startDateStruct":116,"completionDateStruct":118,"leadSponsor":120,"locationsCount":68},"100562251","greater-manchester-cardiovascular-pathology-in-immune-mediated-inflammatory-diseases-100562251","NCT06600737","Greater Manchester CARDIOvascular Pathology in Immune-Mediated Inflammatory Diseases","GM CARDIO-IMID","Main Study\n\nInclusion Criteria:\n\n* Males and females\n* Subjects aged over 18 years\n* Capable of providing informed consent and signing a consent form\n* Have a clear diagnosis of an IMID with history consistent with one of the following categories:\n* IMID-'at risk' CVD: individuals who have a risk of developing CVD (based on traditional risk factors and\u002For IMID-specific factors) but no history of major adverse cardiovascular events (MACE).\n* Incident (new) IMID-CVD: Patients with IMID that present with a MACE.\n* Established IMID-CVD: Patients with IMID and a history of previous MACE\n\nExclusion Criteria:\n\n* Age less than 18 years\n* Lack of capacity to give informed consent\n\nImaging Sub-Study\n\nInclusion Criteria:\n\n\\- As-listed for Main Study\n\nExclusion Criteria:\n\n* As-listed for Main Study and;\n* For the research cardiac MRI imaging component, the following exclusions will apply: pacemakers, surgical clips within the head, certain inner ear implants, neuro-electrical stimulators or metal fragments within the eye or head, pregnancy or breast-feeding. For administration of gadolinium-based contrast agent, GFR \\\u003C 30 ml\u002Fmin\u002F1.73 m2 is a contraindication.\n\nBiological Sub-Study\n\nInclusion Criteria:\n\n\\- As-listed for Main Study\n\nExclusion Criteria:\n\n\\- As-listed for Main Study\n\nControls\n\nInclusion Criteria:\n\n* Subject ≥ 18 years of age\n* Is capable of understanding and signing an informed consent form\n* No known diagnosis of an IMID (CVD-no IMID disease control and healthy control groups)\n* No known diagnosis of CVD (IMID-no risk CVD disease control and healthy control groups)\n\nExclusion Criteria:\n\n* As-listed for Main Study and;\n* For the research cardiac MRI imaging component, the following exclusions will apply: pacemakers, surgical clips within the head, certain inner ear implants, neuro-electrical stimulators or metal fragments within the eye or head, pregnancy or breast-feeding. For administration of gadolinium-based contrast agent, GFR \\\u003C 30 ml\u002Fmin\u002F1.73 m2 is a contraindication.\n\nFor Healthy controls:\n\nThe researchers will aim to identify healthy controls using the 'bring a friend' strategy where the patient is asked to bring a friend\u002Frelative, thus minimising demographic bias. This will establish a healthy control pool. For specific analyses, controls will be age and sex matched and where possible, BMI-matched to the specific study population.",true,{"count":108,"type":21},325,"10 Years","The researchers would like to know more about cardiovascular abnormalities in patients with immune-mediated inflammatory diseases (IMID) and with the aim to provide new biomarkers (clinical, blood, imaging) for early diagnosis, prognosis and prediction of CVD in patients with IMID. This is important as there are still many things that are not known about this and finding out more could improve how patients are treated in future.\n\nParticipants with IMID diagnoses will be recruited from rheumatology\u002Fcardiology departments as in-patients or outpatients.\n\nOnce consented, researchers will collect past, present and future clinical information about them, including routine cardiovascular imaging and blood tests. Participants will also be asked to complete questionnaires at predetermined intervals. The participants could also be approached to take part in the following sub-studies; Biological sub-study, in which blood and urine would be collected; And the Imaging-sub study, in which one or more of Echocardiography, Cardiovascular Magnetic Resonance Imaging (CMR) and Laser Doppler Imaging (LDI) will be performed. Participants with CVD without IMID and healthy volunteers will also be recruited as comparison groups.\n\nThe research is to be funded by the NIHR Manchester BRC ('Integrated Cardiovascular' and 'Rheumatic \\& Musculoskeletal Diseases' themes). Other funding eg Manchester Academic Health Sciences and a recently awarded Medical Research Council Partnership grant will also support this programme. The study will recruit in specialist NHS centres; Recruitment will start in Manchester University Hospitals NHS Foundation Trust.",[112,27],"Cardiovascular Diseases","2024-09-17",{"date":115,"type":36},"2024-09-19",{"date":117,"type":21},"2024-09-30",{"date":119,"type":21},"2032-09-01",{"name":121,"class":43},"University of Manchester",{"id":123,"slug":124,"hasResults":11,"nctId":125,"briefTitle":126,"officialTitle":127,"acronym":128,"eligibilityCriteria":129,"healthyVolunteers":106,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":130,"targetDuration":4,"studyType":55,"phases":4,"briefSummary":132,"conditions":133,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":142,"lastUpdatePostDateStruct":143,"startDateStruct":145,"completionDateStruct":147,"leadSponsor":149,"locationsCount":151},"100533565","a-clinical-study-to-map-the-hla-genomic-region-in-the-greek-population-100533565","NCT06227468","A Clinical Study to Map the HLA Genomic Region in the Greek Population","A Clinical Study to Map the HLA GENomic Region and Its potEntial aSsocIation With Selected diSeases in the Greek Population","GENESIS","Inclusion Criteria:\n\nThe study will include adult subjects (age ≥ 18) that:\n\n* possess a Greek social security number and are visiting hospitals\u002Fclinics, and\u002For other private laboratory institutions (incl. clinics and health care groups) as part of standard clinical practice in Greece,\n* are willing and able to provide written informed consent to participate in the study according to the study protocol.\n\nExclusion Criteria:\n\n* Subjects not able to provide written informed consent (e.g. ICU patients, mental illness patients, lack of legal capacity).\n* Subjects who have had an allogeneic (non-self-donor):\n\n  * bone marrow transplant\n  * stem cell transplant\n  * blood transfusion less than two weeks prior to buccal swab sample collection\n  * liver transplant\n* Subjects who participated in an interventional clinical trial in the past that according to the subject's physician opinion might have had an impact on their HLA genome.",{"count":131,"type":21},12000,"The aim of GENESIS clinical study is to map the HLA genomic region in the Greek population and evaluate possible correlations with selected underlying diseases.",[134,135,136,112,137,138,139,140,141,27],"Healthy","Respiratory Disease","Chronic Renal Failure","Metabolic Disease","Psychiatric Disorder","Neurologic Disorder","Gastrointestinal Diseases","Haematologic Disease","2024-01-25",{"date":144,"type":36},"2024-01-26",{"date":146,"type":36},"2023-12-12",{"date":148,"type":21},"2026-08-31",{"name":150,"class":43},"Athens LifeTech Park",8]